 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Angela Pierce and John DeSisto.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.270 |
|
|
|
-
Balakrishnan I, Madhavan K, Pierce A, Michlin J, Brunt B, Lakshmanachetty S, Wang D, DeSisto J, Nuss ZJ, Davidson N, Walker F, Suresh A, Donson A, Sanford B, Jones KL, Danis EP, Mitra SS, Green AL, Dahl N, Vibhakar R, Venkataraman S. Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma. Cancer Res. 2025 May 27.
Score: 0.062
-
Alimova I, Wang D, DeSisto J, Danis E, Lakshmanachetty S, Prince E, Murdock G, Pierce A, Donson A, Balakrishnan I, Serkova N, Lin H, Foreman NK, Dahl N, Venkataraman S, Vibhakar R. SIRT2 regulates the SMARCB1 loss-driven differentiation block in ATRT. Mol Cancer Res. 2025 Feb 17.
Score: 0.061
-
Veo B, Wang D, DeSisto J, Pierce A, Vibhakar R. Single-cell multi-omics analysis identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma. Res Sq. 2024 Dec 13.
Score: 0.060
-
Moreira DC, Venkataraman S, Subramanian A, Desisto J, Balakrishnan I, Prince E, Pierce A, Griesinger A, Green A, Eberhardt CG, Foreman NK, Vibhakar R. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. J Neurooncol. 2020 May; 147(3):531-545.
Score: 0.043
-
Green AL, Flannery P, Hankinson TC, O'Neill B, Amani V, DeSisto J, Knox A, Chatwin H, Lemma R, Hoffman LM, Mulcahy Levy J, Raybin J, Hemenway M, Gilani A, Koschmann C, Dahl N, Handler M, Pierce A, Venkataraman S, Foreman N, Vibhakar R, Wempe MF, Dorris K. Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa021.
Score: 0.043
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|